Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Mini-Review Article

Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger

In Press, (this is not the final "Version of Record"). Available online 03 October, 2024
Author(s): Xueshuai Ye*, Yongqiang Wu and Haiqiang Zhang
Published on: 03 October, 2024

DOI: 10.2174/0118715206329892240927081033

Price: $95

Open Access Journals Promotions 2
Abstract

Gastric cancer in advanced stages lacked effective treatment options. claudin18.2 (CLDN18.2) is a membrane protein that is crucial for close junctions in the differentiated epithelial cells of the gastric mucosa, playing a vital role in barrier function, and can be hardly recognized by immune cells due to its polarity pattern. As the polarity of gastric tumor cells changes, claudin18.2 is exposed on the cell surface, resulting in immune system recognition, and making it an ideal target. In this review, we summarized the expression regulation mechanism of claudin18.2 both in normal cells and malignant tumor cells. Besides, we analyzed the available clinical results and potential areas for future research on claudin18.2-positive gastric cancer and claudin18.2-targeting therapy. In conclusion, claudin18.2 is an ideal target for gastric cancer treatment, and the claudin18.2-targeting therapy has changed the treatment pattern of gastric cancer.

Keywords: Claudin18.2, gastric cancer, monoclonal antibody, ADC, CAR T


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy